Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of beast cancer bone metastasis

Diptiman Chanda, Tatyana Isayeva, Sanjay Kumar, Gene P. Siegal, April A. Szafran, Kurt R. Zinn, Vishnu V B Reddy, Selvarangan Ponnazhagan

Research output: Contribution to journalArticle

Abstract

Enhanced production of receptor activator of nuclear factor-κB ligand (RANKL) and its binding to RANK on the osteoclasts have been associated with osteolysis in breast cancer bone metastasis. Osteoprotegerin (OPG) is a decoy receptor that prevents RANKL-RANK interaction. This study determined the effects of sustained expression of OPG using a recombinant adeno-associated viral (rAAV) vector in mouse model of osteolytic breast cancer. Bone metastasis was established by intracardiac injection of the human breast cancer cell line MDA-MB-435. Following this, mice were administered a one-time intramuscular injection of rAAV encoding either OPG.Fc (OPG) or green fluorescent protein (GFP). Mice were killed 1 month later and the effects of therapy on tumor growth and bone remodeling were evaluated. Bioluminescence imaging showed significant reduction of tumor growth in bone of OPG.Fc-treated mice. Micro-computed tomography (μCT) analysis and histomorphometry of the tibia indicated significant protection of trabecular and cortical bones after OPG.Fc therapy. Despite the prevention of bone loss and tumor growth in bone, OPG.Fc therapy failed to provide long-term survival. OPG.Fc-treated mice developed more bone than age-matched normal mice, indicating a requirement for regulated transgene expression. Results of this study indicate the potential of rAAV-OPG therapy for reducing morbidity and mortality in breast cancer patients with osteolytic bone damage.

Original languageEnglish (US)
Pages (from-to)871-878
Number of pages8
JournalMolecular Therapy
Volume16
Issue number5
DOIs
StatePublished - May 1 2008
Externally publishedYes

Fingerprint

Osteoprotegerin
Bone Neoplasms
Genetic Therapy
Neoplasm Metastasis
Bone and Bones
Neoplasms
Breast Neoplasms
Therapeutics
Bone Development
Osteolysis
Bone Remodeling
Intramuscular Injections
Osteoclasts
Cytoplasmic and Nuclear Receptors
Green Fluorescent Proteins
Tibia
Transgenes
Tomography
Ligands
Morbidity

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Chanda, D., Isayeva, T., Kumar, S., Siegal, G. P., Szafran, A. A., Zinn, K. R., ... Ponnazhagan, S. (2008). Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of beast cancer bone metastasis. Molecular Therapy, 16(5), 871-878. https://doi.org/10.1038/mt.2008.48

Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of beast cancer bone metastasis. / Chanda, Diptiman; Isayeva, Tatyana; Kumar, Sanjay; Siegal, Gene P.; Szafran, April A.; Zinn, Kurt R.; Reddy, Vishnu V B; Ponnazhagan, Selvarangan.

In: Molecular Therapy, Vol. 16, No. 5, 01.05.2008, p. 871-878.

Research output: Contribution to journalArticle

Chanda, D, Isayeva, T, Kumar, S, Siegal, GP, Szafran, AA, Zinn, KR, Reddy, VVB & Ponnazhagan, S 2008, 'Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of beast cancer bone metastasis', Molecular Therapy, vol. 16, no. 5, pp. 871-878. https://doi.org/10.1038/mt.2008.48
Chanda, Diptiman ; Isayeva, Tatyana ; Kumar, Sanjay ; Siegal, Gene P. ; Szafran, April A. ; Zinn, Kurt R. ; Reddy, Vishnu V B ; Ponnazhagan, Selvarangan. / Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of beast cancer bone metastasis. In: Molecular Therapy. 2008 ; Vol. 16, No. 5. pp. 871-878.
@article{1e9dc085b208498bbdae39d6142f9bc4,
title = "Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of beast cancer bone metastasis",
abstract = "Enhanced production of receptor activator of nuclear factor-κB ligand (RANKL) and its binding to RANK on the osteoclasts have been associated with osteolysis in breast cancer bone metastasis. Osteoprotegerin (OPG) is a decoy receptor that prevents RANKL-RANK interaction. This study determined the effects of sustained expression of OPG using a recombinant adeno-associated viral (rAAV) vector in mouse model of osteolytic breast cancer. Bone metastasis was established by intracardiac injection of the human breast cancer cell line MDA-MB-435. Following this, mice were administered a one-time intramuscular injection of rAAV encoding either OPG.Fc (OPG) or green fluorescent protein (GFP). Mice were killed 1 month later and the effects of therapy on tumor growth and bone remodeling were evaluated. Bioluminescence imaging showed significant reduction of tumor growth in bone of OPG.Fc-treated mice. Micro-computed tomography (μCT) analysis and histomorphometry of the tibia indicated significant protection of trabecular and cortical bones after OPG.Fc therapy. Despite the prevention of bone loss and tumor growth in bone, OPG.Fc therapy failed to provide long-term survival. OPG.Fc-treated mice developed more bone than age-matched normal mice, indicating a requirement for regulated transgene expression. Results of this study indicate the potential of rAAV-OPG therapy for reducing morbidity and mortality in breast cancer patients with osteolytic bone damage.",
author = "Diptiman Chanda and Tatyana Isayeva and Sanjay Kumar and Siegal, {Gene P.} and Szafran, {April A.} and Zinn, {Kurt R.} and Reddy, {Vishnu V B} and Selvarangan Ponnazhagan",
year = "2008",
month = "5",
day = "1",
doi = "10.1038/mt.2008.48",
language = "English (US)",
volume = "16",
pages = "871--878",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of beast cancer bone metastasis

AU - Chanda, Diptiman

AU - Isayeva, Tatyana

AU - Kumar, Sanjay

AU - Siegal, Gene P.

AU - Szafran, April A.

AU - Zinn, Kurt R.

AU - Reddy, Vishnu V B

AU - Ponnazhagan, Selvarangan

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Enhanced production of receptor activator of nuclear factor-κB ligand (RANKL) and its binding to RANK on the osteoclasts have been associated with osteolysis in breast cancer bone metastasis. Osteoprotegerin (OPG) is a decoy receptor that prevents RANKL-RANK interaction. This study determined the effects of sustained expression of OPG using a recombinant adeno-associated viral (rAAV) vector in mouse model of osteolytic breast cancer. Bone metastasis was established by intracardiac injection of the human breast cancer cell line MDA-MB-435. Following this, mice were administered a one-time intramuscular injection of rAAV encoding either OPG.Fc (OPG) or green fluorescent protein (GFP). Mice were killed 1 month later and the effects of therapy on tumor growth and bone remodeling were evaluated. Bioluminescence imaging showed significant reduction of tumor growth in bone of OPG.Fc-treated mice. Micro-computed tomography (μCT) analysis and histomorphometry of the tibia indicated significant protection of trabecular and cortical bones after OPG.Fc therapy. Despite the prevention of bone loss and tumor growth in bone, OPG.Fc therapy failed to provide long-term survival. OPG.Fc-treated mice developed more bone than age-matched normal mice, indicating a requirement for regulated transgene expression. Results of this study indicate the potential of rAAV-OPG therapy for reducing morbidity and mortality in breast cancer patients with osteolytic bone damage.

AB - Enhanced production of receptor activator of nuclear factor-κB ligand (RANKL) and its binding to RANK on the osteoclasts have been associated with osteolysis in breast cancer bone metastasis. Osteoprotegerin (OPG) is a decoy receptor that prevents RANKL-RANK interaction. This study determined the effects of sustained expression of OPG using a recombinant adeno-associated viral (rAAV) vector in mouse model of osteolytic breast cancer. Bone metastasis was established by intracardiac injection of the human breast cancer cell line MDA-MB-435. Following this, mice were administered a one-time intramuscular injection of rAAV encoding either OPG.Fc (OPG) or green fluorescent protein (GFP). Mice were killed 1 month later and the effects of therapy on tumor growth and bone remodeling were evaluated. Bioluminescence imaging showed significant reduction of tumor growth in bone of OPG.Fc-treated mice. Micro-computed tomography (μCT) analysis and histomorphometry of the tibia indicated significant protection of trabecular and cortical bones after OPG.Fc therapy. Despite the prevention of bone loss and tumor growth in bone, OPG.Fc therapy failed to provide long-term survival. OPG.Fc-treated mice developed more bone than age-matched normal mice, indicating a requirement for regulated transgene expression. Results of this study indicate the potential of rAAV-OPG therapy for reducing morbidity and mortality in breast cancer patients with osteolytic bone damage.

UR - http://www.scopus.com/inward/record.url?scp=42549118918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42549118918&partnerID=8YFLogxK

U2 - 10.1038/mt.2008.48

DO - 10.1038/mt.2008.48

M3 - Article

C2 - 18388919

AN - SCOPUS:42549118918

VL - 16

SP - 871

EP - 878

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 5

ER -